Cautious. 9IB.F scores 49/100, held back by weak Leadership Alignment (45/100)—likely dilution concerns or misaligned incentives between founders and shareholders. The company lacks assessed moat strength or structural competitive advantages to offset governance friction. Warrant deeper diligence into cap table and management incentives before committing capital.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for Infant Bacterial Therapeutics N:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 49/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates Infant Bacterial Therapeutics N (9IB.F) at 49/100 — below the bar Stocky looks for. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Cautious. 9IB.F scores 49/100, held back by weak Leadership Alignment (45/100)—likely dilution concerns or misaligned incentives between founders and shareholders. The company lacks assessed moat strength or structural competitive advantage
9IB.F's current Stocky Verdict is 49/100, placing it in the "Cautious" band. This composite combines a 50/100 Compounder score, 45/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for Infant Bacterial Therapeutics N yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
Infant Bacterial Therapeutics N scores 45/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
Vulnerability Profile for Infant Bacterial Therapeutics N covers customer concentration, supply chain risk, refinancing walls, and regulatory exposure. Not yet finalised.
Sign up free and unlock the full analysis on 9IB.F — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
Or jump straight to the interactive dashboard for 9IB.F in the app.
